This study is looking at the safety and effectiveness of a treatment called StroMed and platelet-rich plasma (PRP) for pain and inflammation caused by osteoarthritis (OA) of the shoulder. OA is a condition where the cartilage that cushions your joints wears down. The treatment involves taking your own cells and plasma, processing them, and injecting them directly into your affected shoulder joint. Researchers will measure changes in your arm, shoulder, and hand function using a survey called DASH over six months to see how well the treatment works. You might be able to join if you are between 18 and 90 years old and have shoulder OA. The study is currently unclear on its recruitment status, but plans to enroll up to 4000 patients.

Study design

This is an open-label clinical study, meaning both you and the researchers will know what treatment you are receiving. It will initially involve 50 patients, with a larger follow-up planned for 4,000 patients.

What's involved

You will receive injections into your affected shoulder joint and will need to comply with a treatment plan, laboratory tests, and periodic interviews. Outcomes will be tracked for up to 6 months.

Compensation

Not stated in the trial record.

Follow-up

Your outcomes will be tracked for up to 6 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.